Skip to main content

Table 3 Univariate analysis of prognostic factors in overall survival

From: The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies

Adverse events Median (months) 95% C.I. of median P value Hazard ratio 95% C.I. of HR P value
Skin    .054    
 Grade 0 (n = 32) 5.7 1.3–10.0   1   
 Grade 1–2 (n = 17) 16.4 4.8–28.0   0.49 0.24–1.03 .059
Skin/vitiligo    .047    
 Grade 0 (n = 30) 5.1 3.1–7.2   1   
 Grade 1–2 (n = 19) 16.4 4.8–28.0   0.49 0.24–1.01 .052
Mucositis    .150    
 Grade 0 (n = 46) 11.3 5.6–17.0   1   
 Grade 1–2 (n = 3) 6.0 0.1–13.2   2.36 0.71–7.92 .163
Colitis    .773    
 Grade 0 (n = 43) 13.1 6.9–19.4   1   
 Grade 1–2 (n = 6) 9.7 2.716.6   1.15 0.44–2.98 .773
Liver    .292    
 Grade 0 (n = 47) 10.7 5.3–16.2   1   
 Grade 1–2 (n = 1) 9.7   1.55 0.21–11.50 .670
 Grade 3–5 (n = 1) 2.8   4.33 0.55–33.91 .162
Lung    .001    
 Grade 0 (n = 47) 10.7 6.2–15.3   1   
 Grade 3–5 (n = 2) 0.9   8.90 1.83–43.4 .007
Endocrine    .062    
 Grade 0 (n = 40) 8.8 2.4–15.3   1   
 Grade 1–2 (n = 9) 18.7 2.0–35.3   0.38 0.13–1.09 .073
Fatigue    .019    
 Grade 0 (n = 42) 11.3 6.1–16.4   1   
 Grade 1–2 (n = 7) 3.7 1.3–6.2   2.69 1.14–6.34 .024
Vitiligo    .856    
 Grade 0 (n = 47) 10.7 7.3–14.2   1   
 Grade 1–2 (n = 2) 8.1   0.83 0.11–6.16 .856
Skin/vitiligo/endocrine    .002    
 Grade 0 (n = 26) 4.5 0.9–8.1   1   
 Any grade (n = 23) 18.7 6.2–31.1   0.34 0.17–0.69 .003
Overall    <.001    
 Grade 0 (n = 19) 5.7 0.1–11.7   1   
 Grade 1–2 (n = 27) 15.2 7.9–22.5   0.50 0.24–1.02 .058
 Grade 3–5 (n = 3) 2.0 0.2–3.8   5.13 1.29–20.34 .020
  1. C.I. confidence interval